Gleason 4级模式总长度与Grade Group 2-4前列腺癌主动监测资格
本研究纳入2499例MRI靶向联合系统活检诊断为GG2-4且行根治性前列腺切除术的患者,评估总GP4长度是否比现有风险分组标准更能预测主动监测资格。结果显示GP4<2mm者无论GG如何,不良病理和5年生化复发风险与有利中危组相似,若以此作为阈值可使约两倍患者符合主动监测条件。
要点
- GP4<2mm者不良病理风险5.2%对5.0%,5年BCR 20%对21%,与有利中危组相似
- 以GP4<2mm为阈值,主动监测资格患者约增加一倍
- GP4总长度量化方法和最佳截点尚未确定,需进一步研究
核心结论
- GP4总长度比现有有利中危组标准能更好地对主动监测资格进行风险分层。
研究设计与样本
- 回顾性队列研究,纳入2499例MRI靶向联合系统活检诊断为GG2-4且行根治性前列腺切除术的患者。
- GG2、GG3、GG4分别有1691、694、114例,其中73%、19%、15%的患者GP4长度<2mm。
主要发现
- GP4<2mm者无论GG如何,不良病理风险为5.2%对5.0%,5年BCR为20%对21%,与有利中危组相似。
- 以GP4<2mm作为主动监测阈值,可使约两倍患者符合主动监测资格,仅美国每年约5万人。
关键数值与推荐
- GP4总长度计算为系统穿刺核心GP4毫米数总和加上MRI靶向穿刺核心的平均值。
- GP4<2mm被评估为潜在主动监测阈值。
临床怎么用
- 临床可考虑将GP4总长度纳入主动监测资格评估,但需先明确量化方法和最佳截点。
局限性
- GP4最佳量化方法和合适截点尚未确定,临床实施前需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether total Gleason pattern 4 (GP4) length provides better risk stratification than current risk group criteria for determining potential active surveillance (AS) eligibility, using oncological outcomes after radical prostatectomy (RP). PATIENTS AND METHODS: We identified patients with Grade Group (GG) 2-4 disease on magnetic resonance imaging (MRI)-targeted and systematic biopsy who underwent RP. We calculated total GP4 length as the summed millimetres of GP4 in systematic cores plus the average across MRI-targeted cores. Concordance analysis was used to evaluate how increasing GG corresponded to greater GP4 burden. We compared prediction of adverse pathology at RP and 5-year biochemical recurrence (BCR) between risk groups and total length of GP4. RESULTS: Among 2499 patients, 1691, 694, and 114 had GG2, GG3, and GG4 disease, of whom 73%, 19%, and 15% had low amounts (<2 mm) of GP4. Patients with <2 mm of GP4, regardless of GG, had similar risks of adverse pathology (5.2% vs 5.0%) and 5-year BCR (20% vs 21%) as those with favourable intermediate-risk disease; if used as an AS threshold, <2 mm of GP4 would classify approximately twice as many patients as AS eligible, translating to ~50 000 men annually in the United States alone. CONCLUSIONS: Total length of GP4 provides better risk stratification for AS eligibility than current favourable intermediate-risk group criteria. Further defining the optimal method for GP4 quantification and determining the appropriate cut-point is needed before clinical implementation.
引用
- Fletcher SA, Pickersgill NA, Aiken N, et al. Gleason pattern 4 length and active surveillance eligibility in Grade Group 2-4 prostate cancer. BJU Int. 2026. PMID: 42830647. doi:10.1111/bju.70478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。